论文部分内容阅读
现代生物技术很大程度上得益于20世纪70年代建立和发展的重组DNA技术和淋巴细胞杂交瘤技术。前者导致了许多新基因的克隆、新蛋白的发现和新型基因工程药物的生产;后者产生的单克隆抗体技术改变,促进了整个生命科学及生物技术的发展。毫不夸张地说,没有杂交瘤和单克隆抗体技术,就没有今天的生命科学和生物技术。基于重组DNA技术和杂交瘤技术而建立的抗体工程,在20世纪80-90年代得到了长足的发展。通过抗体工程获得的抗体在生命科学的基础研究、临床疾病的诊断、抗肿瘤的治疗、抗移植物排
Modern biotechnology has benefited a lot from recombinant DNA technology and lymphocyte hybridoma technology that was established and developed in the 1970s. The former led to the cloning of many new genes, the discovery of new proteins and the production of novel genetically engineered drugs; the latter produced monoclonal antibody technology changes that have contributed to the development of life sciences and biotechnology in general. It is no exaggeration to say that without hybridoma and monoclonal antibody technology there is no life science and biotechnology today. Antibody engineering based on recombinant DNA technology and hybridoma technology has made great strides in the 1980s and 1990s. Antibodies obtained by antibody engineering Basic research in life sciences, diagnosis of clinical diseases, anti-tumor therapy, anti-graft row